Core value dossier for a treatment used in stages III, IV and V renal disease
Core value dossier in the treatment of secondary hyperparathyroidism associated with chronic kidney disease including end stage renal disease
Core value dossier in chronic kidney disease and end stage renal disease
Literature review of the burden of depression in hemodialysis patients (in chronic kidney disease)
Pilot utility elicitation study in end stage renal disease
Logistical costs of changing treatment in chronic kidney disease
Capturing costs when switching from one ESA to another for chronic kidney disease in UK hospital trusts
Payer research to understand potential pricing and reimbursement in polycystic kidney disease
Disease area review, burden of illness and unmet needs in heart failure (and associated renal dysfunction)
Meta-analysis of a treatment for chronic kidney disease: trials and PRO endpoints
Manuscripts and conference attendance for a treatment in chronic kidney disease
FDA meeting support in defence of PRO claims for a treatment for chronic kidney disease
Manuscript and advisory board on physical functioning in chronic kidney disease
Development of a manuscript and production of two posters on the symptoms of chronic kidney disease when treated with a specific drug
Review of a dossier in chronic kidney disease
Qualitative interviews, conceptual model and strategic consulting on autosomal dominant polycystic kidney disease (ADPKD)
Measures for use in patients with autosomal dominant polycystic kidney and liver disease: development and validation of a symptom measure and validation of a health survey
Regulatory consulting on claims with the FDA for a treatment for end stage renal disease (ESRD)
Relevance and context of information for a treatment for hyperphosphatemia in patients with chronic kidney disease
Preparation of a manuscript on the relevance of pharmacoeconomics studies in renal disease
Literature research and assessment of the appetite and activities of daily living in patients with end-stage renal disease
Payer objection handlers to support treatment in secondary hyperparathyroidism (SHPT)
Consultation on an FDA PRO claim in nephrology
COA strategies to complement a biology and renal/fibrotic portfolio
Qualitative literature and instrument review in atypical Haemolytic Uremic Syndrome (aHUS)
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreACCEPTREJECT
Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
We’d like to set analytic software i.e. Google Analytics/Click Dimensions to help us improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone. For more information on how these cookies work, please see our Cookies Policy.